Startseite Naturwissenschaften 17. TARGETING ZINC(II) SIGNALLING TO PREVENT CANCER
Kapitel
Lizenziert
Nicht lizenziert Erfordert eine Authentifizierung

17. TARGETING ZINC(II) SIGNALLING TO PREVENT CANCER

  • Silvia Ziliotto , Olivia Ogle und Kathryn M. Taylor
Veröffentlichen auch Sie bei De Gruyter Brill
Erkunden Sie dieses Fachgebiet So veröffentlichen Sie bei uns
Metallo-Drugs: Development and Action of Anticancer Agents
Ein Kapitel aus dem Buch Metallo-Drugs: Development and Action of Anticancer Agents

Abstract

Zinc is an important element that is gaining momentum as a potential target for cancer therapy. In recent years zinc has been accepted as a second messenger that is now recognized to be able to activate many signalling pathways within a few minutes of an extracellular stimulus by release of zinc(II) from intracellular stores. One of the major effects of this store release of zinc is to inhibit a multitude of tyrosine phosphatases which will prevent the inactivation of tyrosine kinases and hence, encourage further activation of tyrosine kinasedependent signalling pathways. Most of these signalling pathways are not only known to be involved in driving aberrant cancer growth, they are usually the main driving force. All this data together now positions zinc and zinc signalling as potentially important new targets to prevent aggressive cancer growth.

Abstract

Zinc is an important element that is gaining momentum as a potential target for cancer therapy. In recent years zinc has been accepted as a second messenger that is now recognized to be able to activate many signalling pathways within a few minutes of an extracellular stimulus by release of zinc(II) from intracellular stores. One of the major effects of this store release of zinc is to inhibit a multitude of tyrosine phosphatases which will prevent the inactivation of tyrosine kinases and hence, encourage further activation of tyrosine kinasedependent signalling pathways. Most of these signalling pathways are not only known to be involved in driving aberrant cancer growth, they are usually the main driving force. All this data together now positions zinc and zinc signalling as potentially important new targets to prevent aggressive cancer growth.

Kapitel in diesem Buch

  1. Frontmatter i
  2. About the Editors v
  3. Historical Development and Perspectives of the Series vii
  4. Preface to Volume 18 ix
  5. Contents xiii
  6. Contributors to Volume 18 xix
  7. Titles of Volumes 1–44 in the Metal Ions in Biological Systems Series xxiii
  8. Contents of Volumes in the Metal Ions in Life Sciences Series xxv
  9. 1. CISPLATIN AND OXALIPLATIN: OUR CURRENT UNDERSTANDING OF THEIR ACTIONS 1
  10. 2. POLYNUCLEAR PLATINUM COMPLEXES. STRUCTURAL DIVERSITY AND DNA BINDING 43
  11. 3. PLATINUM(IV) PRODRUGS 69
  12. 4. METALLOGLYCOMICS 109
  13. 5. THE DECEPTIVELY SIMILAR RUTHENIUM(III) DRUG CANDIDATES KP1019 AND NAMI-A HAVE DIFFERENT ACTIONS. WHAT DID WE LEARN IN THE PAST 30 YEARS? 141
  14. 6. MULTINUCLEAR ORGANOMETALLIC RUTHENIUM-ARENE COMPLEXES FOR CANCER THERAPY 171
  15. 7. MEDICINAL CHEMISTRY OF GOLD ANTICANCER METALLODRUGS 199
  16. 8. COORDINATION COMPLEXES OF TITANIUM(IV) FOR ANTICANCER THERAPY 219
  17. 9. HEALTH BENEFITS OF VANADIUM AND ITS POTENTIAL AS AN ANTICANCER AGENT 251
  18. 10. GALLIUM COMPLEXES AS ANTICANCER DRUGS 281
  19. 11. NON-COVALENT METALLO-DRUGS: USING SHAPE TO TARGET DNA AND RNA JUNCTIONS AND OTHER NUCLEIC ACID STRUCTURES 303
  20. 12. NUCLEIC ACID QUADRUPLEXES AND METALLO-DRUGS 325
  21. 13. ANTITUMOR METALLODRUGS THAT TARGET PROTEINS 351
  22. 14. METALLOINTERCALATORS AND METALLOINSERTORS: STRUCTURAL REQUIREMENTS FOR DNA RECOGNITION AND ANTICANCER ACTIVITY 387
  23. 15. IRON AND ITS ROLE IN CANCER DEFENSE: A DOUBLE-EDGED SWORD 437
  24. 16. COPPER COMPLEXES IN CANCER THERAPY 469
  25. 17. TARGETING ZINC(II) SIGNALLING TO PREVENT CANCER 507
  26. SUBJECT INDEX 531
https://doi.org/10.1515/9783110470734-017

Kapitel in diesem Buch

  1. Frontmatter i
  2. About the Editors v
  3. Historical Development and Perspectives of the Series vii
  4. Preface to Volume 18 ix
  5. Contents xiii
  6. Contributors to Volume 18 xix
  7. Titles of Volumes 1–44 in the Metal Ions in Biological Systems Series xxiii
  8. Contents of Volumes in the Metal Ions in Life Sciences Series xxv
  9. 1. CISPLATIN AND OXALIPLATIN: OUR CURRENT UNDERSTANDING OF THEIR ACTIONS 1
  10. 2. POLYNUCLEAR PLATINUM COMPLEXES. STRUCTURAL DIVERSITY AND DNA BINDING 43
  11. 3. PLATINUM(IV) PRODRUGS 69
  12. 4. METALLOGLYCOMICS 109
  13. 5. THE DECEPTIVELY SIMILAR RUTHENIUM(III) DRUG CANDIDATES KP1019 AND NAMI-A HAVE DIFFERENT ACTIONS. WHAT DID WE LEARN IN THE PAST 30 YEARS? 141
  14. 6. MULTINUCLEAR ORGANOMETALLIC RUTHENIUM-ARENE COMPLEXES FOR CANCER THERAPY 171
  15. 7. MEDICINAL CHEMISTRY OF GOLD ANTICANCER METALLODRUGS 199
  16. 8. COORDINATION COMPLEXES OF TITANIUM(IV) FOR ANTICANCER THERAPY 219
  17. 9. HEALTH BENEFITS OF VANADIUM AND ITS POTENTIAL AS AN ANTICANCER AGENT 251
  18. 10. GALLIUM COMPLEXES AS ANTICANCER DRUGS 281
  19. 11. NON-COVALENT METALLO-DRUGS: USING SHAPE TO TARGET DNA AND RNA JUNCTIONS AND OTHER NUCLEIC ACID STRUCTURES 303
  20. 12. NUCLEIC ACID QUADRUPLEXES AND METALLO-DRUGS 325
  21. 13. ANTITUMOR METALLODRUGS THAT TARGET PROTEINS 351
  22. 14. METALLOINTERCALATORS AND METALLOINSERTORS: STRUCTURAL REQUIREMENTS FOR DNA RECOGNITION AND ANTICANCER ACTIVITY 387
  23. 15. IRON AND ITS ROLE IN CANCER DEFENSE: A DOUBLE-EDGED SWORD 437
  24. 16. COPPER COMPLEXES IN CANCER THERAPY 469
  25. 17. TARGETING ZINC(II) SIGNALLING TO PREVENT CANCER 507
  26. SUBJECT INDEX 531
Jetzt anmelden und 20% sparen
Institutioneller Zugang
Wie funktioniert Authentifizierung?
Haben Sie eine Idee, wie wir unsere Website verbessern können?
Bitte schreiben Sie uns.
© 2025 De Gruyter Brill
Heruntergeladen am 22.9.2025 von https://www.degruyterbrill.com/document/doi/10.1515/9783110470734-017/html
Button zum nach oben scrollen